S&P 500   5,064.99 (+1.67%)
DOW   38,898.74 (+0.74%)
QQQ   435.45 (+2.31%)
AAPL   182.90 (+0.32%)
MSFT   410.86 (+2.16%)
META   485.01 (+3.63%)
GOOGL   143.97 (+1.00%)
AMZN   172.48 (+2.31%)
TSLA   194.11 (-0.34%)
NVDA   776.86 (+15.14%)
NIO   5.75 (-3.69%)
AMD   180.23 (+9.70%)
BABA   75.52 (-0.08%)
T   16.61 (-2.29%)
F   12.21 (+0.58%)
MU   85.39 (+4.79%)
CGC   3.42 (-0.58%)
GE   151.79 (+1.82%)
DIS   108.13 (+0.43%)
AMC   4.58 (+0.22%)
PFE   27.27 (-1.45%)
PYPL   57.54 (+0.10%)
XOM   104.38 (-0.45%)
S&P 500   5,064.99 (+1.67%)
DOW   38,898.74 (+0.74%)
QQQ   435.45 (+2.31%)
AAPL   182.90 (+0.32%)
MSFT   410.86 (+2.16%)
META   485.01 (+3.63%)
GOOGL   143.97 (+1.00%)
AMZN   172.48 (+2.31%)
TSLA   194.11 (-0.34%)
NVDA   776.86 (+15.14%)
NIO   5.75 (-3.69%)
AMD   180.23 (+9.70%)
BABA   75.52 (-0.08%)
T   16.61 (-2.29%)
F   12.21 (+0.58%)
MU   85.39 (+4.79%)
CGC   3.42 (-0.58%)
GE   151.79 (+1.82%)
DIS   108.13 (+0.43%)
AMC   4.58 (+0.22%)
PFE   27.27 (-1.45%)
PYPL   57.54 (+0.10%)
XOM   104.38 (-0.45%)
S&P 500   5,064.99 (+1.67%)
DOW   38,898.74 (+0.74%)
QQQ   435.45 (+2.31%)
AAPL   182.90 (+0.32%)
MSFT   410.86 (+2.16%)
META   485.01 (+3.63%)
GOOGL   143.97 (+1.00%)
AMZN   172.48 (+2.31%)
TSLA   194.11 (-0.34%)
NVDA   776.86 (+15.14%)
NIO   5.75 (-3.69%)
AMD   180.23 (+9.70%)
BABA   75.52 (-0.08%)
T   16.61 (-2.29%)
F   12.21 (+0.58%)
MU   85.39 (+4.79%)
CGC   3.42 (-0.58%)
GE   151.79 (+1.82%)
DIS   108.13 (+0.43%)
AMC   4.58 (+0.22%)
PFE   27.27 (-1.45%)
PYPL   57.54 (+0.10%)
XOM   104.38 (-0.45%)
S&P 500   5,064.99 (+1.67%)
DOW   38,898.74 (+0.74%)
QQQ   435.45 (+2.31%)
AAPL   182.90 (+0.32%)
MSFT   410.86 (+2.16%)
META   485.01 (+3.63%)
GOOGL   143.97 (+1.00%)
AMZN   172.48 (+2.31%)
TSLA   194.11 (-0.34%)
NVDA   776.86 (+15.14%)
NIO   5.75 (-3.69%)
AMD   180.23 (+9.70%)
BABA   75.52 (-0.08%)
T   16.61 (-2.29%)
F   12.21 (+0.58%)
MU   85.39 (+4.79%)
CGC   3.42 (-0.58%)
GE   151.79 (+1.82%)
DIS   108.13 (+0.43%)
AMC   4.58 (+0.22%)
PFE   27.27 (-1.45%)
PYPL   57.54 (+0.10%)
XOM   104.38 (-0.45%)

Monopar Therapeutics (MNPR) News Today

$1.15
+0.58 (+101.96%)
(As of 10:22 AM ET)
SourceHeadline
finance.yahoo.com logoMonopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
finance.yahoo.com - February 22 at 7:38 AM
benzinga.com logoCrude Oil Moves Lower; Summit Therapeutics Shares Plummet
benzinga.com - February 20 at 3:02 PM
marketwatch.com logoMonopar Therapeutics Shares Surge on Australia Antibody-Trial Clearance
marketwatch.com - February 20 at 3:02 PM
msn.com logoWhy Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?
msn.com - February 20 at 3:02 PM
marketbeat.com logo
marketbeat.com - February 20 at 10:30 AM
marketbeat.com logo
marketbeat.com - February 20 at 10:22 AM
finance.yahoo.com logoMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
finance.yahoo.com - February 20 at 10:01 AM
marketbeat.com logo
marketbeat.com - February 20 at 9:51 AM
marketbeat.com logo
marketbeat.com - February 20 at 9:41 AM
marketbeat.com logo
marketbeat.com - February 20 at 9:36 AM
globenewswire.com logoMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
globenewswire.com - February 20 at 8:00 AM
MarketBeat logoMonopar Therapeutics (NASDAQ:MNPR) Trading Up 0.7%
americanbankingnews.com - February 20 at 2:24 AM
reuters.com logoKyverna Therapeutics Inc
reuters.com - February 10 at 3:30 AM
finance.yahoo.com logoMonopar Therapeutics Inc. (MNPR)
finance.yahoo.com - January 7 at 5:23 PM
finance.yahoo.com logoMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
finance.yahoo.com - November 9 at 9:32 AM
finance.yahoo.com logoMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
finance.yahoo.com - November 9 at 9:32 AM
finance.yahoo.com logoMonopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs
finance.yahoo.com - November 9 at 9:32 AM
markets.businessinsider.com logoPromising Early Efficacy Results and Diverse Drug Development Portfolio Drive ‘Buy’ Rating for Monopar Therapeutics Inc
markets.businessinsider.com - November 3 at 7:06 AM
finance.yahoo.com logoMonopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
finance.yahoo.com - November 1 at 8:11 AM
finance.yahoo.com logoMonopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
finance.yahoo.com - October 10 at 7:57 AM
finance.yahoo.com logoMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 5 at 5:52 PM
finance.yahoo.com logoMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 5 at 7:12 AM
finance.yahoo.com logoMonopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
finance.yahoo.com - August 10 at 10:06 AM
finance.yahoo.com logoMonopar Provides Encouraging Camsirubicin Clinical Data Update
finance.yahoo.com - August 8 at 7:39 AM
finance.yahoo.com logoMonopar Provides Encouraging Camsirubicin Clinical Data Update
finance.yahoo.com - August 8 at 7:39 AM
finance.yahoo.com logoMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
finance.yahoo.com - July 11 at 8:36 AM
finance.yahoo.com logoMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
finance.yahoo.com - July 11 at 8:36 AM
finance.yahoo.com logoMonopar to Participate in the Radiopharma Forum by the Lake 2023
finance.yahoo.com - June 21 at 10:19 AM
finance.yahoo.com logoMonopar to Participate in the Maxim Group’s Healthcare Virtual Conference
finance.yahoo.com - June 14 at 9:41 AM
msn.com logoHC Wainwright & Co. Reiterates Monopar Therapeutics (MNPR) Buy Recommendation
msn.com - June 1 at 8:19 PM
finance.yahoo.com logoMonopar Announces Encouraging Camsirubicin Phase 1b Trial Update
finance.yahoo.com - June 1 at 10:18 AM
finance.yahoo.com logoMonopar Announces Encouraging Camsirubicin Phase 1b Trial Update
finance.yahoo.com - June 1 at 10:18 AM
marketbeat.com logo
marketbeat.com - May 30 at 10:03 AM
finance.yahoo.com logoMonopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
finance.yahoo.com - May 29 at 1:59 PM
markets.businessinsider.com logoExpert Ratings for Monopar Therapeutics
markets.businessinsider.com - May 15 at 2:00 PM
msn.com logoHC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy Recommendation
msn.com - May 15 at 2:00 PM
markets.businessinsider.com logoMonopar Therapeutics Inc (MNPR) Gets a Buy from H.C. Wainwright
markets.businessinsider.com - May 15 at 8:59 AM
investing.com logoMonopar Therapeutics (MNPR) Earnings Dates & Reports
investing.com - May 13 at 9:05 AM
marketwatch.com logo10-Q: MONOPAR THERAPEUTICS
marketwatch.com - May 11 at 9:18 PM
finanznachrichten.de logoMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
finanznachrichten.de - May 11 at 10:50 AM
finance.yahoo.com logoMonopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
finance.yahoo.com - May 11 at 10:50 AM
finance.yahoo.com logoMonopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
finance.yahoo.com - May 11 at 10:50 AM
msn.com logoMaxim Group Downgrades Monopar Therapeutics (MNPR)
msn.com - March 30 at 10:41 AM
finanznachrichten.de logoMonopar Therapeutics Inc.: Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
finanznachrichten.de - March 29 at 9:06 AM
marketwatch.com logoMonopar Therapeutics Shares Plumb New Lows After Validive Failure >MNPR
marketwatch.com - March 28 at 2:52 PM
finance.yahoo.com logoMonopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication
finance.yahoo.com - March 28 at 2:52 PM
markets.businessinsider.com logoMonopar To Discontinue Phase 2b/3 VOICE Trial Along With Active Development Of Validive
markets.businessinsider.com - March 28 at 9:44 AM
msn.com logoMonopar stock crashes ~50% as Validive program gets axed after trial failure
msn.com - March 28 at 9:44 AM
msn.com logoMonopar Tanks After Validive Fails Cancer Trial
msn.com - March 28 at 9:44 AM
marketwatch.com logoMonopar Therapeutics Shares Plummet Premarket After Validive Failure >MNPR
marketwatch.com - March 28 at 9:44 AM
Get Monopar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.



MNPR Media Mentions By Week

MNPR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MNPR
News Sentiment

0.11

0.49

Average
Medical
News Sentiment

MNPR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MNPR Articles
This Week

12

1

MNPR Articles
Average Week

Get Monopar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:MNPR) was last updated on 2/22/2024 by MarketBeat.com Staff